The Neurology of Dysautonomia: POTS, Orthostatic Intolerance, and Autonomic Testing in 2026

The Core Clinical Message for Evaluating Dysautonomia in 2026

The neurologic evaluation of dysautonomia begins by separating symptoms from syndromes, and syndromes from underlying mechanisms. Palpitations, lightheadedness, cognitive slowing, fatigue, nausea, tremulousness, visual dimming, and exercise intolerance frequently occur during orthostatic stress, but none of these are specific to POTS. Likewise, a large heart rate increase is not diagnostic when it happens during dehydration, anemia, fever, endocrine disease, medication exposure, prolonged bed rest, or another acute physiologic stressor.[1-3]

POTS remains a syndrome defined by chronic orthostatic symptoms and a characteristic hemodynamic response, not by tachycardia alone. Autonomic testing should therefore be ordered specifically to answer a stated clinical question.[1-3] The principal questions usually include:

• Does the patient meet criteria for POTS or another orthostatic hemodynamic syndrome?
• Is there objective evidence of generalized or regional autonomic failure?
• Is a postganglionic small-fiber process demonstrable?
• Is the presentation better explained by a cardiac, hematologic, endocrine, medication-related, volume-related, vestibular, functional, or other neurologic disorder?

Making this distinction prevents two incredibly common clinical errors: labeling every orthostatic symptom as POTS, and incorrectly excluding POTS simply because a broad autonomic reflex screen is normal.[1,3]

Understanding Dysautonomia as an Umbrella Term Rather Than a Single Diagnosis

The term dysautonomia describes disordered autonomic function across cardiovascular, sudomotor, gastrointestinal, genitourinary, pupillary, thermoregulatory, and other domains. It can reflect a primary autonomic neurodegenerative disorder, an immune-mediated or paraneoplastic autonomic neuropathy, diabetes or another systemic neuropathy, medication toxicity, spinal cord or brainstem disease, a focal small-fiber neuropathy, or even a functional disturbance of orthostatic regulation. POTS occupies only a specific part of this wide spectrum.[3,4]

Orthostatic intolerance is similarly broader than POTS. It simply refers to symptoms provoked by upright posture and improved by sitting or lying down. The hemodynamic correlate may be POTS, classic orthostatic hypotension, initial orthostatic hypotension, delayed orthostatic hypotension, vasovagal physiology, or no conventional heart rate or blood pressure threshold at all during the observed test.[4,5]

A diagnostic label should always identify the observed syndrome before assigning a proposed mechanism. Terms like neuropathic POTS, hyperadrenergic POTS, and hypovolemic POTS may describe useful physiologic patterns, but they are not always mutually exclusive, uniformly defined, or stable over time.[1,3]

The Neurologic and Physiologic Mechanics of Standing

When a person stands, blood rapidly shifts toward the lower extremities and splanchnic circulation, causing venous return and stroke volume to fall. In response, arterial and cardiopulmonary baroreceptors increase sympathetic outflow, reduce parasympathetic cardiac influence, accelerate the heart rate, and constrict resistance and capacitance vessels. Skeletal muscle pumping and neurohumoral responses then work together to preserve cerebral perfusion.[1,3,4]

Orthostatic symptoms can emerge when one or more parts of this compensatory system are inadequate or disproportionate. Potential contributors in POTS include reduced effective central blood volume, excessive venous pooling, partial sympathetic denervation, impaired vasoconstriction, low stroke volume, heightened sympathetic activation, altered respiratory control, physical deconditioning, and postinfectious or immune-associated changes. These mechanisms frequently overlap, and the available evidence does not support reducing POTS to a single unifying cause.[1,3]

It is crucial to remember that tachycardia in POTS is often compensatory. Suppressing the heart rate without considering blood pressure, stroke volume, venous pooling, and overall symptom physiology may improve one specific measurement while simultaneously worsening another aspect of orthostatic tolerance.[1,3]

Defining the Diagnostic Criteria for Postural Orthostatic Tachycardia Syndrome

For patients aged 20 years or older, contemporary criteria require a sustained heart rate increase of at least 30 beats per minute within 10 minutes of standing or head-up tilt. For patients aged 12 to 19 years, the threshold is at least 40 beats per minute. The increase should be demonstrated on at least two measurements separated by at least one minute, accompanied by frequent orthostatic symptoms that improve with recumbence, a symptom duration of at least 3 months, and the absence of any other condition that adequately explains the sinus tachycardia.[2,5]

A substantial, sustained drop in blood pressure that meets the criteria for classic orthostatic hypotension strongly argues against POTS as the primary explanation for the patient’s symptoms during that test. Brief initial orthostatic hypotension may coexist, however, and does not by itself exclude POTS.[2,4]

These criteria should never be applied mechanically. Orthostatic heart rate responses naturally vary with the time of day, hydration status, ambient temperature, recent meals, sleep quality, menstrual factors, medications, nicotine, caffeine, anxiety, pain, and intercurrent illness. A patient with a convincing chronic history and a negative afternoon test may merit a standardized morning reassessment rather than immediate diagnostic closure.[1,2]

Major Orthostatic Patterns to Distinguish

Phenotype	Typical observed pattern	Clinical interpretation
POTS	Sustained HR rise meeting the age threshold within 10 minutes, chronic orthostatic symptoms, and no sustained classic OH	Requires symptom concordance and exclusion of secondary sinus tachycardia.[2,5]
Classic OH	Sustained BP fall of at least 20 mm Hg systolic or 10 mm Hg diastolic within 3 minutes	Consider neurogenic and non-neurogenic causes; evaluate HR compensation and medication or volume factors.[4]
Initial OH	Transient BP fall within about 15 seconds, often with rapid recovery	Best detected with beat-to-beat BP; an intermittent cuff may miss it.[4,6]
Delayed OH	Orthostatic BP fall meeting the OH threshold after 3 minutes	May require prolonged stand or tilt; interpret with symptom timing, medications, and the broader neurologic examination.[4,6]
Vasovagal syncope	Delayed hypotension, often with relative or absolute bradycardia, plus a typical prodrome	History and symptom reproduction matter; a positive tilt is not interpreted in isolation.[4]
Orthostatic symptoms without a conventional HR/BP threshold	Upright symptoms occur without meeting POTS or OH criteria during the test	Reassess the protocol, timing, respiratory pattern, medications, arrhythmia, and nonautonomic mimics.[1]

Abbreviations: BP, blood pressure; HR, heart rate; OH, orthostatic hypotension; POTS, postural orthostatic tachycardia syndrome.

The Critical Role of History and Physical Examination Before Testing

A high-quality history often determines which test is actually worth performing. Clinicians should characterize the latency after standing, the duration of tolerated upright posture, recovery with recumbence, true loss of consciousness, specific triggers, heat sensitivity, meal effects, menstrual associations, fluid intake, gastrointestinal losses, infection onset, activity restriction, and post-exertional worsening. It is also vital to ask whether symptoms occur only when upright, or if they also happen when seated, supine, or during exertion.[1-3]

Medication reconciliation is absolutely essential. Stimulants, norepinephrine reuptake inhibitors, vasodilators, diuretics, thyroid hormone excess, beta-agonists, and withdrawal from rate-controlling or sedating drugs can all significantly alter orthostatic physiology. Medication changes before testing should occur only when clinically safe and explicitly directed by the care team.[2,3]

The physical examination should include supine and upright heart rate and blood pressure, cardiac auscultation, volume-status clues, peripheral neuropathy screening, reflexes, gait, cerebellar signs, parkinsonism, pupillary responses, sweating distribution, skin color changes, venous pooling, and joint hypermobility when relevant. Hypermobile features, migraine, gastrointestinal symptoms, fatigue, and allergic symptoms may certainly coexist with POTS, but their presence does not prove a single shared mechanism.[1-3]

An electrocardiogram is highly appropriate in the initial assessment. Ambulatory rhythm monitoring is useful when episodes are abrupt, occur without posture change, wake the patient from sleep, or raise concern for supraventricular tachycardia or inappropriate sinus tachycardia. Echocardiography and other cardiac testing should be driven by the examination, electrocardiographic findings, exertional symptoms, or structural heart disease risk rather than ordered routinely for every single patient.[2]

Basic laboratory evaluation should be targeted to plausible secondary causes. Depending on the clinical context, this may include a complete blood count, electrolytes and renal function, thyroid testing, ferritin or iron studies, glucose assessment, pregnancy testing, or other directed studies. Broad autoimmune, infectious, endocrine, or nutritional panels ordered without a supporting history can easily produce incidental findings and lead to diagnostic drift.[2,3]

The 10-Minute Active Stand as the Initial Physiologic Assessment

A properly performed active stand is accessible, inexpensive, and usually sufficient to document the orthostatic heart rate response required for a POTS assessment.[1,2] Importantly, it also preserves the physiologic contribution of active standing and the skeletal muscle pump.

A practical and standardized protocol includes:

1. Allow 5 to 10 minutes of quiet supine rest.
2. Record baseline heart rate and blood pressure near the end of the supine period.
3. Ask the patient to stand directly and remain still without leaning, walking, talking, or repeatedly contracting the leg muscles.
4. Measure heart rate and blood pressure serially through 10 minutes, commonly at 1, 3, 5, 8, and 10 minutes.
5. Record symptoms and their specific timing, not just the maximum heart rate.
6. Stop the test immediately for presyncope, severe symptoms, unsafe blood pressure, or an inability to remain upright.

Whenever possible, document room temperature, time of day, recent food and fluid intake, caffeine or nicotine exposure, and medications that may influence the result. These conditions are not trivial metadata; they directly affect reproducibility and the clinical meaning of a borderline result.[1,2,6]

Intermittent automated blood pressure cuffs are adequate for many routine POTS assessments, but they can easily miss abrupt initial orthostatic hypotension. Continuous beat-to-beat blood pressure monitoring is preferable when early blood pressure transients, delayed recovery, recurrent syncope, or subtle adrenergic impairment are central to the clinical question.[6]

Why Active Stand and Head-Up Tilt Testing Are Not Interchangeable

Head-up tilt testing removes the active effort of standing and reduces skeletal muscle pump activity. Because of this, it can generate a larger heart rate rise than an active stand in the exact same person. In a 2025 same-day study of 60 patients with established POTS, 74% met the conventional heart rate criterion during a 10-minute active stand, compared with 98% during head-up tilt. Tilt also produced a larger overall heart rate increment.[7] Because the study evaluated a known POTS cohort with a fixed test order, its classification percentages should not be generalized directly to unselected diagnostic populations.

The clinical implication is not that tilt is universally superior. Rather, the method must be carefully recorded and interpreted in context. An active stand is generally preferable as the initial test when the patient can stand safely. Tilt is particularly useful in the following settings:[1,2,7,8]

• The patient cannot stand safely or reliably.
• Recurrent unexplained syncope requires controlled symptom reproduction.
• Delayed orthostatic hypotension or vasovagal physiology is strongly suspected.
• Beat-to-beat blood pressure and a standardized passive orthostatic stress are needed.
• A standardized stand is negative or equivocal despite a strong, persistent clinical history.
• The clinician needs to distinguish orthostatic symptoms from psychogenic pseudosyncope or another transient loss-of-consciousness phenotype.

Tilt testing requires continuous beat-to-beat blood pressure, electrocardiographic monitoring, trained supervision, and a protocol matched to the specific clinical question.[8,9] Interpretation remains anchored to the presenting history and the reproduced clinical event.[10] Pharmacologic provocation can increase sensitivity for reflex syncope, but it also changes specificity and should never be used merely to force a positive result.

A single negative stand or tilt does not necessarily exclude POTS when the history is compelling and test conditions were suboptimal. Conversely, an isolated threshold-positive tilt in a minimally symptomatic patient does not establish a chronic syndrome.[1,2,7]

How the Autonomic Reflex Screen Addresses a Different Clinical Question

A laboratory autonomic reflex screen generally evaluates three distinct domains:

• Cardiovagal function: Heart rate variability during deep breathing and the cardiovagal response during the Valsalva maneuver.
• Adrenergic function: Beat-to-beat blood pressure responses during the Valsalva maneuver and orthostatic challenge.
• Postganglionic sudomotor function: Quantitative sudomotor axon reflex testing (QSART), where available.

No single component is sufficient to fully characterize autonomic function. Results are interpreted together, often with an integrated severity score such as the Composite Autonomic Severity Score (CASS).[9]

The reflex screen is most useful when the clinician suspects generalized autonomic failure, autonomic neuropathy, a regional postganglionic sudomotor lesion, or an orthostatic blood pressure disorder. It is not a mandatory confirmatory test for every patient with otherwise well-characterized POTS. Many patients with POTS simply do not have the diffuse cardiovagal, adrenergic, and sudomotor deficits seen in generalized autonomic failure.[1,3,9]

Therefore, a normal CASS or a normal autonomic reflex screen does not negate a valid POTS diagnosis. It simply indicates that the tested domains did not demonstrate generalized autonomic failure under the specific laboratory conditions.[3,9]

Match the Test to the Clinical Question

Clinical question	Most useful test	Key interpretive limit
Does the patient meet POTS hemodynamic criteria?	Standardized 10-minute active stand; tilt when indicated	The threshold must be paired with chronic symptoms, the BP response, and exclusion of secondary tachycardia.[1,2]
Is there initial or delayed OH?	Beat-to-beat active stand or prolonged tilt	Intermittent cuffs may miss rapid initial BP changes.[4,6,8]
Is generalized autonomic failure present?	Reflex screen with cardiovagal, adrenergic, and sudomotor testing	A normal result does not exclude POTS.[3,9]
Is postganglionic sudomotor dysfunction present?	QSART	An abnormality supports a sudomotor lesion but is not specific for POTS.[9]
What is the whole-body sweat distribution?	Thermoregulatory sweat test	Availability is limited; pairing with QSART may help localize preganglionic versus postganglionic dysfunction.[9]
Is small-fiber loss demonstrable?	Skin biopsy for intraepidermal nerve-fiber density	Supports small-fiber neuropathy in the correct phenotype; does not independently diagnose POTS.[11,12]
Is hyperadrenergic physiology suspected?	Standardized supine and upright plasma catecholamines in selected patients	Collection conditions and medications strongly affect results; an elevated value is not a stand-alone disease label.[1,3]
Could the episodes be arrhythmic?	ECG and ambulatory rhythm monitoring	These are cardiac rhythm tests, not autonomic-function tests.[2]

Abbreviations: BP, blood pressure; ECG, electrocardiogram; OH, orthostatic hypotension; POTS, postural orthostatic tachycardia syndrome; QSART, quantitative sudomotor axon reflex test.

The Role of Small-Fiber Testing in Selected Neuropathic Phenotypes

A neuropathic contribution is highly plausible when POTS coexists with distal burning pain, sensory loss, altered temperature perception, patchy or distal sweating abnormalities, dependent color change, or other evidence of small-fiber dysfunction. In a small 2013 study, combined structural and functional criteria identified a neuropathic pattern in 9 of 24 participants with POTS.[11] The study was informative but far too small to define a universal POTS subtype.

A larger retrospective tertiary-center analysis found reduced sweat output in 33% of patients who underwent QSART and reduced intraepidermal nerve-fiber density in 24% of those who underwent skin biopsy.[12] Because testing was clinically selected rather than applied uniformly, those percentages should not be interpreted as true population prevalence.

Skin biopsy and QSART provide complementary information. Skin biopsy evaluates structural small-fiber density at sampled sites, while QSART evaluates postganglionic sudomotor function. Discordance is entirely possible, and neither test establishes the underlying cause of a neuropathy. Positive findings should trigger a directed etiologic evaluation based on age, tempo, distribution, systemic features, and examination rather than an indiscriminate laboratory panel.[9,11,12]

Evaluating Catecholamines, Autoantibodies, and Emerging Physiologic Measures

Standardized supine and upright plasma catecholamine measurements can support a hyperadrenergic pattern in selected patients, especially when orthostatic symptoms include prominent tremor, adrenergic surges, or blood pressure elevation. Collection should carefully account for posture duration, medication effects, nicotine, caffeine, and acute stress. The result must always be integrated with the broader clinical and hemodynamic picture.[1,3]

Commercial G protein-coupled receptor autoantibody panels should not be used as routine diagnostic tests for POTS. In a 2022 case-control study, concentrations measured by a commercially available enzyme-linked immunosorbent assay did not reliably distinguish 116 patients with POTS from 81 healthy controls.[13] Research into immune mechanisms remains incredibly important, but a research hypothesis is not equivalent to a validated clinical assay.

Transcranial Doppler, extracranial Doppler, end-tidal carbon dioxide, near-infrared spectroscopy, and other cerebral perfusion measures may identify physiologic abnormalities in patients whose symptoms occur without conventional heart rate or blood pressure criteria. A 2024 observational study described orthostatic cerebral hypoperfusion and hypocapnia in such patients.[14] These methods remain specialized or research-oriented and should not be presented as established stand-alone diagnostic criteria for POTS.

Symptom questionnaires such as the COMPASS-31 can beautifully quantify autonomic symptom burden and track change over time, but they do not identify the hemodynamic syndrome or localize a lesion. A high symptom score should prompt careful evaluation, not substitute for it.[3,9]

Navigating POTS and Post-Acute Sequelae of SARS-CoV-2 Infection

POTS and other orthostatic syndromes can certainly occur after SARS-CoV-2 infection, but prevalence estimates depend heavily on referral patterns and specific case definitions. In a prospective study comparing 33 patients with post-acute sequelae of SARS-CoV-2 infection, 33 patients with POTS, and 33 healthy controls, 79% of the post-COVID group met POTS criteria during the study assessment.[15] That enriched, referred cohort does not imply that 79% of all people with long COVID have POTS.

The exact same diagnostic discipline applies after infection. Clinicians should document the orthostatic phenotype, exclude anemia, cardiopulmonary disease, endocrine disease, medication effects, dehydration, and other postinfectious complications, and then select testing based on the unresolved clinical question.[2,3,15]

Recognizing Neurologic and Cardiac Red Flags That Require Broader Evaluation

A straightforward POTS pathway is entirely insufficient when the patient has progressive or widespread autonomic failure. Features that should prompt a broader neurologic evaluation include:[3,9]

• New urinary retention, severe erectile dysfunction, or progressive gastrointestinal dysmotility with weight loss.
• Generalized or segmental anhidrosis.
• Fixed pupillary abnormalities.
• Objective sensory loss, weakness, ataxia, parkinsonism, or upper motor neuron signs.
• Rapidly progressive autonomic symptoms.
• A subacute syndrome with severe orthostatic hypotension, gastrointestinal dysmotility, or other features concerning for immune, paraneoplastic, toxic, or neurodegenerative autonomic disease.

Cardiac red flags include syncope during exertion or while supine, a family history of sudden death, structural heart disease findings, an abnormal electrocardiogram, abrupt-onset regular tachycardia, chest pain with exertion, or sustained arrhythmia. These presentations require a prompt cardiac evaluation rather than casual attribution to POTS.[2,8]

A Practical Step-by-Step Neurologic Testing Sequence

Step 1: Define the Clinical Event

Determine whether the dominant problem is chronic orthostatic intolerance, recurrent syncope, episodic tachycardia, progressive autonomic failure, distal small-fiber symptoms, or a mixture. Establish posture dependence and recovery with recumbence.[1-3]

Step 2: Identify Immediate Mimics and Hazards

Review medications, hydration, blood loss, infection, pain, sleep, nutrition, endocrine symptoms, substance exposure, and deconditioning. Obtain an electrocardiogram and targeted laboratory studies. Escalate cardiac or neurologic red flags before pursuing a routine POTS label.[2,3]

Step 3: Perform Standardized Orthostatic Vitals

Use a 10-minute active stand with symptom recording when safe. Repeat under better standardized conditions when a borderline or negative result conflicts with a strong chronic history.[1,2,6]

Step 4: Select Tilt Testing for a Specific Reason

Use tilt when passive orthostatic stress, continuous hemodynamics, prolonged observation, syncope evaluation, delayed orthostatic hypotension assessment, or safe testing without active standing is required.[7,8,10]

Step 5: Add the Reflex Screen When Lesion Localization Matters

Order cardiovagal, adrenergic, and sudomotor testing when the concern extends beyond POTS to autonomic failure, autonomic neuropathy, or a regional sudomotor disorder.[9]

Step 6: Add Phenotype-Specific Studies Selectively

Consider skin biopsy, thermoregulatory sweat testing, standardized catecholamines, ambulatory rhythm monitoring, or focused etiologic studies only when the result can resolve a defined differential or change management.[1,9,11-13]

Ensuring That Autonomic Testing Directly Changes Clinical Management

The immediate management of orthostatic intolerance often begins long before an advanced laboratory study is available. Correct reversible causes, review aggravating medications, educate the patient about triggers, and consider fluid and sodium strategies when not contraindicated. Compression garments, physical countermeasures, and a graduated, individualized activity program may be highly useful.[1-3,16] Exercise studies remain heterogeneous, and programs should be adjusted for baseline function, comorbidity, and symptom tolerance rather than prescribed as a uniform cure.[16]

Pharmacologic treatment for POTS is phenotype-directed and remains off-label in the United States. No medication has an FDA indication specifically for POTS.[3] Ivabradine labeling addresses selected patients with heart failure, not POTS.[17] Midodrine is labeled for symptomatic orthostatic hypotension and carries a prominent warning about marked supine hypertension; its use for POTS is also off-label.[18] Drug selection should carefully account for resting and upright blood pressure, heart rate pattern, volume status, pregnancy potential, renal and hepatic function, drug interactions, and the distinct possibility that the tachycardia is compensatory.

Autonomic testing is most valuable when it directly changes this plan. Demonstrated neurogenic orthostatic hypotension, diffuse autonomic failure, a postganglionic sudomotor lesion, an arrhythmia, or a small-fiber neuropathy can redirect treatment and etiologic investigation. A broad test battery that does not address a specific clinical decision simply adds cost and can generate confusing incidental abnormalities.[3,9,11,12]

Avoiding Common Diagnostic Pitfalls in Dysautonomia Evaluation

• Using a wearable heart rate trace as the diagnosis: Consumer devices can document patterns and help identify timing, but they usually do not provide validated simultaneous blood pressure, controlled posture, or exclusion of competing causes.[2,6]
• Diagnosing POTS during acute illness or volume depletion: The syndrome requires chronicity and the explicit exclusion of a condition that adequately explains the tachycardia.[2]
• Treating every positive tilt as POTS: Tilt can amplify tachycardia, and the result must reproduce the relevant syndrome in the appropriate clinical setting.[7,8]
• Assuming normal autonomic reflex testing excludes POTS: The reflex screen assesses autonomic domains and lesion severity; POTS can easily be present without generalized autonomic failure.[3,9]
• Calling every abnormal skin biopsy “neuropathic POTS”: Reduced nerve-fiber density supports small-fiber neuropathy but does not prove that the neuropathy caused the orthostatic syndrome.[11,12]
• Ordering commercial autoantibody panels as confirmatory tests: Available commercial GPCR antibody testing has not demonstrated adequate diagnostic discrimination.[13]
• Conflating association with causation: Hypermobile features, migraine, postinfectious onset, gastrointestinal symptoms, mast-cell symptoms, fatigue, and sleep disturbance may cluster in patients with POTS, but co-occurrence does not establish a single causal pathway.[1,3]

Acknowledging Current Limitations and Future Research Priorities

POTS research still faces variable protocols, referral bias, inconsistent phenotype definitions, small cohorts, and limited long-term controlled treatment data. Active stand and tilt can classify the exact same patient differently, and many mechanistic studies are cross-sectional or conducted in highly selected autonomic centers.[1,7]

A narrative review published on August 10, 2026, again highlighted diagnostic delay, test heterogeneity, and misdiagnosis.[19] Its proximity to this article’s review cutoff limits full appraisal, so it is used here as a contemporaneous signal rather than as the principal support for a clinical recommendation.

Future priorities include protocol standardization, age- and method-specific reference data, biomarkers that distinguish mechanism rather than symptom burden, longitudinal studies after infection, clinically meaningful treatment outcomes, and better integration of cerebral perfusion, respiratory physiology, small-fiber measures, and conventional hemodynamics.[1,7,19]

 

References

1. Lau DH, Fedorowski A, Raj SR, et al. Postural Orthostatic Tachycardia Syndrome: A State-of-the-Art Review. Heart Lung Circ. 2026;35(2):171-185. DOI | PubMed PMID: 41519610
2. Raj SR, Fedorowski A, Sheldon RS. Diagnosis and management of postural orthostatic tachycardia syndrome. CMAJ. 2022;194(10). DOI | PubMed PMID: 35288409
3. Vernino S, Bourne KM, Stiles LE, et al. Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting, Part 1. Auton Neurosci. 2021;235:102828. DOI | PubMed PMID: 34144933
4. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69-72. DOI | PubMed PMID: 21431947
5. Raj SR, Guzman JC, Harvey P, et al. Canadian Cardiovascular Society Position Statement on Postural Orthostatic Tachycardia Syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance. Can J Cardiol. 2020;36(3):357-372. DOI | PubMed PMID: 32145864
6. Finucane C, van Wijnen VK, Fan CW, et al. A practical guide to active stand testing and analysis using continuous beat-to-beat non-invasive blood pressure monitoring. Clin Auton Res. 2019;29(4):427-441. DOI | PubMed PMID: 31076939
7. Uppal J, Baker JR, Hira R, et al. Physiological and clinical comparison of active stand and head-up tilt tests in patients with postural orthostatic tachycardia syndrome. Auton Neurosci. 2025;260:103281. DOI | PubMed PMID: 40273723
8. Thijs RD, Brignole M, Falup-Pecurariu C, et al. Recommendations for tilt table testing and other provocative cardiovascular autonomic tests in conditions that may cause transient loss of consciousness. Clin Auton Res. 2021;31(3):369-384. DOI | PubMed PMID: 33740206
9. Cheshire WP, Freeman R, Gibbons CH, et al. Electrodiagnostic assessment of the autonomic nervous system: A consensus statement endorsed by the American Autonomic Society, American Academy of Neurology, and the International Federation of Clinical Neurophysiology. Clin Neurophysiol. 2021;132(2):666-682. DOI | PubMed PMID: 33419664
10. Cheshire WP Jr, Goldstein DS. Autonomic Uprising: The Tilt Table Test in Autonomic Medicine. Clin Auton Res. 2019;29(2):215-230. DOI | PubMed PMID: 30838497
11. Gibbons CH, Bonyhay I, Benson A, Wang N, Freeman R. Structural and functional small fiber abnormalities in the neuropathic postural tachycardia syndrome. PLoS One. 2013;8(12). DOI | PubMed PMID: 24386408
12. Zhang R, Mayuga K, Shields R, Cantrell C, Wilson R. Skin Biopsy and Quantitative Sudomotor Axon Reflex Testing in Patients With Postural Orthostatic Tachycardia Syndrome. Cureus. 2022;14(11). DOI | PubMed PMID: 36349067
13. Hall J, Bourne KM, Vernino S, et al. Detection of G Protein-Coupled Receptor Autoantibodies in Postural Orthostatic Tachycardia Syndrome Using Standard Methodology. Circulation. 2022;146(8):613-622. DOI | PubMed PMID: 35766055
14. Novak P, Systrom DM, Witte A, Marciano SP. Orthostatic intolerance with tachycardia and without orthostatic hypotension: hypocapnic cerebral hypoperfusion. Front Neurol. 2024;15:1476918. DOI | PubMed PMID: 39544990
15. Seeley MC, Gallagher C, Ong E, et al. High Incidence of Autonomic Dysfunction and Postural Orthostatic Tachycardia Syndrome in Patients With Long-COVID: Implications for Management and Health Care Planning. Am J Med. 2025;138(2):354-361.e1. DOI | PubMed PMID: 37391116
16. Cortez MM, Aikins K, Arnold AC, et al. Impact of exercise to treat postural orthostatic tachycardia syndrome: a systematic review. Front Neurol. 2025;16:1567708. DOI | PubMed PMID: 40365455
17. DailyMed. Ivabradine tablet, film coated: official prescribing information. National Library of Medicine. Accessed August 12, 2026. Official prescribing information
18. DailyMed. Midodrine hydrochloride tablets, USP: official prescribing information. Updated January 13, 2026. National Library of Medicine. Accessed August 12, 2026. Official prescribing information
19. Tiotsop M, Roger D, Sama R, Ande E, Salabei J. Diagnostic strategies, test accuracy, and misdiagnosis of postural orthostatic tachycardia syndrome: a narrative review of diagnostic criteria, tests, and diagnostic delay. Clin Auton Res. Published online August 10, 2026. DOI | PubMed PMID: 42573959